Chest Computed Tomography Receipt Beyond 5 Years After Lung Cancer Diagnosis and Survival

Importance Long-term lung cancer (LC) survivors remain at risk of LC events (LCEs), including late recurrence and second primary LC, beyond 5 years after diagnosis, but the role of computed tomography (CT) surveillance beyond 5 years remains uncertain. Objective To evaluate whether CT receipt beyond 5 years after LC diagnosis is associated with LCEs and survival. Design, Setting, and Participants This nationwide population-based cohort study used sequential target trial emulation with monthly eligibility reassessment and time-updated propensity score matching based on data from the Korean National Health Insurance Service database. Patients diagnosed with LC from 2006 to 2019 were followed up through December 31, 2024. Long-term LC survivors were eligible for trial entry 5.5 years after diagnosis if they had no administrative evidence of active or recurrent LC, a prior LCE, or another primary cancer. Data were analyzed between January 1, 2026, and February 28, 2026. Exposures CT receipt beyond 5 years after LC diagnosis, defined as chest CT during the 1-month assessment window at each monthly trial baseline, compared with no CT receipt. Main Outcomes and Measures The primary outcome was LCE occurrence, defined by new LC-specific special copayment registration after the monthly trial baseline. Secondary outcomes were all-cause mortality, surgical resection after LCE detection, and subsequent mortality. Results The cohort of 55 694 LC survivors (mean [SD] age, 63.3 [10.9] years; 58.0% male) contributed 2 629 462 eligible person-trials. Matching yielded 583 756 person-trials per group. During a median (IQR) follow-up of 2.74 (1.16-5.18) years, CT receipt was associated with a higher incidence of LCEs (2.49% vs 1.97% per year; hazard ratio [HR], 1.28 [95% CI, 1.26-1.29]) and lower all-cause mortality rate (2.62% vs 4.33% per year; HR, 0.66 [95% CI, 0.65-0.67]) compared with no CT receipt. Among patients with an LCE, CT receipt was associated with greater odds of surgical resection after LCE (odds ratio, 1.46 [95% CI, 1.41-1.52]) and a lower subsequent mortality risk (HR, 0.63 [95% CI, 0.61-0.64]). These associations were observed more frequently among females (HR, 0.47 [95% CI, 0.44-0.49]), older adults (HR, 0.57 [95% CI, 0.54-0.60]), and never smokers (HR, 0.55 [95% CI, 0.53-0.57]). Conclusions and Relevance In this cohort study, CT receipt beyond 5 years after LC diagnosis was associated with increased detection of LCEs, greater use of surgical resection after an LCE, and a lower all-cause mortality rate. These findings support further evaluation of risk-adapted CT surveillance beyond 5 years in selected LC survivors.

Authors

Institutions

Publication Details

Journal
JAMA Oncology
Published
2026-11-19
DOI
https://doi.org/10.1001/jamaoncol.2026.4659
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Chest Computed Tomography Receipt Beyond 5 Years After Lung Cancer Diagnosis and Survival

Dong Woog Yoon, Danbee Kang, Sun Hwa Lee, Byeong‐Ho Jeong et al.
JAMA Oncology
Lung Cancer Diagnosis and Treatment
article

Chest Computed Tomography Receipt Beyond 5 Years After Lung Cancer Diagnosis and Survival

Dong Woog Yoon, Danbee Kang, Sun Hwa Lee, Byeong‐Ho Jeong, Dong Wook Shin, Hea Lim Choi, Hong Kwan Kim, Juwon Park
article en

Abstract

Importance Long-term lung cancer (LC) survivors remain at risk of LC events (LCEs), including late recurrence and second primary LC, beyond 5 years after diagnosis, but the role of computed tomography (CT) surveillance beyond 5 years remains uncertain. Objective To evaluate whether CT receipt beyond 5 years after LC diagnosis is associated with LCEs and survival. Design, Setting, and Participants This nationwide population-based cohort study used sequential target trial emulation with monthly eligibility reassessment and time-updated propensity score matching based on data from the Korean National Health Insurance Service database. Patients diagnosed with LC from 2006 to 2019 were followed up through December 31, 2024. Long-term LC survivors were eligible for trial entry 5.5 years after diagnosis if they had no administrative evidence of active or recurrent LC, a prior LCE, or another primary cancer. Data were analyzed between January 1, 2026, and February 28, 2026. Exposures CT receipt beyond 5 years after LC diagnosis, defined as chest CT during the 1-month assessment window at each monthly trial baseline, compared with no CT receipt. Main Outcomes and Measures The primary outcome was LCE occurrence, defined by new LC-specific special copayment registration after the monthly trial baseline. Secondary outcomes were all-cause mortality, surgical resection after LCE detection, and subsequent mortality. Results The cohort of 55 694 LC survivors (mean [SD] age, 63.3 [10.9] years; 58.0% male) contributed 2 629 462 eligible person-trials. Matching yielded 583 756 person-trials per group. During a median (IQR) follow-up of 2.74 (1.16-5.18) years, CT receipt was associated with a higher incidence of LCEs (2.49% vs 1.97% per year; hazard ratio [HR], 1.28 [95% CI, 1.26-1.29]) and lower all-cause mortality rate (2.62% vs 4.33% per year; HR, 0.66 [95% CI, 0.65-0.67]) compared with no CT receipt. Among patients with an LCE, CT receipt was associated with greater odds of surgical resection after LCE (odds ratio, 1.46 [95% CI, 1.41-1.52]) and a lower subsequent mortality risk (HR, 0.63 [95% CI, 0.61-0.64]). These associations were observed more frequently among females (HR, 0.47 [95% CI, 0.44-0.49]), older adults (HR, 0.57 [95% CI, 0.54-0.60]), and never smokers (HR, 0.55 [95% CI, 0.53-0.57]). Conclusions and Relevance In this cohort study, CT receipt beyond 5 years after LC diagnosis was associated with increased detection of LCEs, greater use of surgical resection after an LCE, and a lower all-cause mortality rate. These findings support further evaluation of risk-adapted CT surveillance beyond 5 years in selected LC survivors.

JAMA Oncology
Samsung Medical Center (KR), Sungkyunkwan University (KR)
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon